

# Cohort – TwinsUK

<https://www.neurodegenerationresearch.eu/survey/cohort-twinsuk/>

## Title of the cohort

Cohort – TwinsUK

## Acronym for cohort

TUK

## Name of Principal Investigator

Title Prof

First name Tim

Last name Spector

## Address of institution where award is held

Institution Dep. of Twin Research & Genetic Epidemiology

Street Address Westminster Bridge Road

City London

Postcode SE1 7EH

## Country

United Kingdom

## Website

<http://www.twin-research.ac.uk/>

## Contact email

[email protected]

## Funding source

The main funding bodies currently supporting TwinsUK are the Wellcome Trust, European Union (EU), and National Institute for Health Research (NIHR)

### 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Parkinson's disease

### When studies on the above condition(s) are expected to become possible

Already possible

### 2a. Stated aim of the cohort

The TwinsUK is an adult twin British registry shown to be representative of the United Kingdom population

## **2b. Features distinguishing this cohort from other population cohorts**

Healthy Twins cohort

### **3a. i) Number of publications that involve use of cohort to date**

600

### **3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

### **3b. Publication list/link to where data or publications are accessible (if available)**

<http://www.twin-research.ac.uk/publications.html>

## **3c. Information (i.e. research findings) expected to be gained from the population cohort**

### **4a. Study criteria: age range of participants at recruitment**

Age in years from: 18

To ('until death' if applicable): until death (or retirement from the study)

### **4b. Study criteria: inclusion criteria**

No inclusion criteria

### **4c. Study criteria: exclusion criteria**

No exclusion criteria

## **5. Size of the cohort (i.e. number of participants enrolled)**

10,001 – 15,000 participants

## **6a. Measures used to characterise participants**

Clinical visit and questionnaire

## **6b. Additional measures for participants with a clinical disorder**

No

## **6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

No

## **7. Study design**

- Prospective cohort

## **8. Cases matched by**

- Other health assessment (specify) / N/A

- no match

**9a. Does the study include a specialised subset of control participants**

No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

01-01-1992

**10a. ii) Data collection end date**

**10a. iii) Data collection for this study is**

Data collection ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

- Yes – intend to apply for funding

**11. Data collected**

Only through the study

**12. System in place to enable re-contact with patients for future studies**

Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

Yes/No % available

Data summarised in database Yes

Database is web-based no

Database on spreadsheet no

Database is on paper no

Other (specify)

**Language used:**

English

**13b. Format and availability of data held as individual records**

Yes/No % available

Data held as individual records yes

Data is web-based no

Data held on computer based records yes

Data held on cards no

Other (specify)

**Language used:**

English

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- Resource has own ethics approval so usually no need for separate external ethics approval

**15. Data sharing policy specified as a condition of use**

Data made publicly available after a specified time point

**16a. Are tissues/samples/DNA available to other groups**

No

**16b. i) Description of available tissues/samples/DNA**

**16b. ii) Form available tissues/samples/DNA are supplied in**

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**